RNA interference in pain research

Journal of Neurochemistry

Volumn 99, Issue 2, 2006, Pages 371-380

  Röhl, Thomas ^a   Kurreck, Jens ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Gene silencing; Pain; RNA interference; Small interfering RNA; Target validation; Viral delivery

Indexed keywords

ADENOVIRUS VECTOR; ANALGESIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; COMPLEMENTARY RNA; DOXYCYCLINE; IMMUNOLIPOSOME; LIPID; MACROGOL; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PENETRATIN; PLASMID DNA; POLYETHYLENEIMINE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STABLE NUCLEIC ACID LIPID PARTICLE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

AMYOTROPHIC LATERAL SCLEROSIS; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM; COMPLEX FORMATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG TARGETING; EXPRESSION VECTOR; GENE SILENCING; GENETIC ANALYSIS; HUMAN; HYPOTHESIS; IN VIVO STUDY; MAMMAL; MEDICAL RESEARCH; MOLECULAR STABILITY; NERVE CELL; NEUROPATHIC PAIN; NEUROSCIENCE; NONHUMAN; PAIN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SPINOCEREBELLAR DEGENERATION; TISSUE DISTRIBUTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WEIGHT REDUCTION;

ANIMALS; CENTRAL NERVOUS SYSTEM; GENE TARGETING; GENETIC VECTORS; HUMANS; NERVE TISSUE PROTEINS; PAIN; RECEPTORS, CELL SURFACE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VIRUSES;

MAMMALIA;

EID: 33749167739     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04082.x     Document Type: Review

References (74)

1. Bernstein E., Caudy A. A., Hammond S. M. and Hannon G. J. (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409, 363-366.
2. Blisky E. J., Bernstein R. N., Hruby V. J., Rothman R. B., Lai J. and Porreca F. (1996) Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated 'knock-down' of opioid receptor in vivo. J. Pharmacol. Exp. Ther. 220, 491-501.
3. Bridge A. J., Pebernard S., Ducraux A., Nicoulaz A. L. and Iggo R. (2003) Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 34, 263-264.
4. Clemens M. J. and Elia A. (1997) The double-stranded RNA-dependent protein kinase PKR: structure and function. J. Interferon Cytokine Res. 17, 503-524.
5. Cortright D. N. and Szallasi A. (2004) Biochemical pharmacology of the vanilloid receptor TRPV1. Eur. J. Biochem. 271, 1814-1819.
6. Czauderna F., Fechtner M., Dames S., Aygün H., Klippel A., Pronk G. J., Giese K. and Kaufmann J. (2003a) Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucl Acids Res. 31, 2705-2716.
7. Czauderna F., Santel A., Hinz M. et al. (2003b) Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res. 31, e127.
8. Davidson T. J., Harel S., Arboleda V. A., Prunell G. F., Shelanski M. L., Greene L. A. and Troy C. M. (2004) Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. J. Neurosci. 24, 10 040-10 046.
9. Dorn G., Abdel'Al S., Natt F. J., Weiler J., Hall J., Meigel I., Mosbacher J. and Wishart W. (2001) Specific inhibition of the rat ligand-gated ion channel P2X3 function via methoxyethoxy-modified phosphorothioated antisense oligonucleotides. Antisense Nucl. Acid Drug Dev. 11, 165-174.
10. Dorn G., Patel S., Wotherspoon G. et al. (2004) siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 32, e49.
11. Eckstein F. (2005) Small non-coding RNAs as magic bullets. Trends Biochem. Sci. 30, 445-452.
12. Elbashir S. M., Harborth J., Lendeckel W., Yalcin A., Weber K. and Tuschl T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
13. Fire A., Xu S., Montgomery M. K., Kostas S. A., Driver S. E. and Mello C. C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811.
14. Ganju P. and Hall J. (2004) Potential applications of siRNA for pain therapy. Exp. Opin. Biol. Ther. 4, 531-542.
15. Garber K. (2005) Peptide leads new class of chronic pain drugs. Nat. Biotechnol. 23, 399.
16. Ge Q., Filip L., Bai A., Nguyen T., Eisen H. N. and Chen J. (2004) Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl Acad. Sci. USA 101, 8676-8681.
17. Gillen C. and Maul C. (2002) New pharmacological strategies for pain relief. Expert Rev. Neurotherapeutics 2, 89-101.
18. Godbey W. T., Wu K. K. and Mikos A. G. (1999) Tracking the intracellular path of poly (ethylenimine) /DNA complexes for gene delivery. Proc. Natl Acad. Sci. USA 96, 5177-5181.
19. Grünweller A. and Hartmann R. K. (2005) RNA interference as a genespecific approach for molecular medicine. Curr. Med. Chem. 12, 3143-3163.
20. Grünweller A., Wyszko E., Bieber B., Jahnel R., Erdmann V. A. and Kurreck J. (2003) Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 31, 3185-3193.
21. Guo W., Robbins M. T., Wei F., Zou S., Dubner R. and Ren K. (2006) Supraspinal brain-derived neurotrophic factor signaling: a novel mechanism for descending pain facilitation. J. Neurosci. 26, 126-137.
22. Hannon G. J. (2002) RNA interference. Nature 418, 244-251.
23. 3 receptor. Nucleic Acids Res. 31, 2117-2126.
24. Hescheler J., Rosenthal W., Trautwein W. and Schultz G. (1987) The GTP-binding protein, Go, regulates neuronal calcium channels. Nature 325, 445-447.
25. Isacson R., Kull B., Salmi P. and Wahlestedt C. (2003) Lack of efficacy of 'naked' small interfering RNA applied directly to rat brain. Acta Physiol. Scand. 179, 173-177.
26. Jackson A. L. and Linsley P. S. (2004) Noise amidst the silence: off-target effects of siRNAs? Trends Genet. 20, 521-524.
27. 2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc. Natl Acad. Sci. USA 99, 17 179-17 184.
28. Julius D. and Basbaum A. I. (2001) Molecular mechanisms of nociception. Nature 413, 203-210.
29. Kennedy S., Wang D. and Ruvkun G. (2004) A conserved siRNA-degrading RNase negatively regulates RNA interference in C. elegans. Nature 427, 645-649.
30. Kim S., Kang C., Shin C. Y. et al. (2006) TRPV1 recapitulates native capsaicin receptor in sensory neurons in association with Fas-associated factor 1. J. Neurosci. 26, 2403-2412.
31. Krichevsky A. M. and Kosik K. S. (2002) RNAi functions in cultured mammalian neurons. Proc. Natl Acad. Sci. USA 99, 11 926-11 929.
32. van der Krol A. R., Mur L. A., Beld M., Mol J. N. and Stuitje A. R. (1990) Flavonoid genes in petunia: addition of a limited number of gene copies may lead to a suppression of gene expression. Plant Cell. 2, 291-299.
33. Kurreck J. (2004) Antisense and RNA interference approaches to target validation in pain research. Cur. Opinion Drug Discov. Dev. 7, 179-187.
34. Lai J., Gold M. S., Kim C.-S., Bian D., Ossipov M. H., Hunter J. C. and Porreca F. (2002) Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain 95, 143-152.
35. Lang J., Nishimoto I., Okamoto T., Regazzi R., Kiraly C., Weller U. and Wollheim C. B. (1995) Direct control of exocytosis by receptor-mediated activation of the heterotrimeric GTPases Gi and Go or by the expression of their active G alpha subunits. EMBO J. 14, 3635-3644. Erratum in. EMBO J. 14, 4639.
36. Leung R. K. and Whittaker P. A. (2005) RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Ther. 107, 222-239.
37. Lewis C., Neidhart S., Holy C., North R. A., Buell G. and Surprenant A. (1995) Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons. Nature 377, 432-435.
38. Luo M.-C., Zhang D.-Q., Ma S.-W., Huang Y.-Y., Shuster S. J., Porreca F. and Lai J. (2005) An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol. Pain 1, 29.
39. Matranga C., Tomari Y., Shin C., Bartel D. P. and Zamore P. D. (2005) Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123, 607-620.
40. 2/3 receptor antagonist, on neuropathic, inflammatory and chemogenic nociception following intrathecal and intraplantar administration. Br. J. Pharmacol. 140, 1381-1388.
41. Meister G. and Tuschl T. (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343-349.
42. Morrissey D. V., Lockridge J. A., Shaw L. et al. (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 23, 1002-1007.
43. Napoli C., Lemieux C. and Jorgensen R. (1990) Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans. Plant Cell 2, 279-289.
44. Pardridge W. M. (2004) Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin. Biol. Ther. 4, 1103-1113.
45. Player M. R. and Torrence P. F. (1998) The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol. Ther. 78, 55-113.
46. Porreca F., Lai J., Bian D. et al. (1999) A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc. Natl Acad. Sci. USA 96, 7640-7644. Erratum in Proc. Natl Acad. Sci. USA 96, 10 548.
47. Ralph G. S., Radcliffe P. A., Day D. M. et al. (2005) Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 11, 429-422.
48. Rand T. A., Petersen S., Du F. and Wang X. (2005) Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell 123, 621-629.
49. Raoul C., Abbas-Terki T. Bensadoun J. C. Guillot S. Haase G. Szulc J. Henderson C. E. and Aebischer P. (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 11, 423-428.
50. Rice A. S. C. and Hill R. G. (2006) New treatments for neuropathic pain. Annu. Rev. Med. 57, 535-551.
51. Romano N. and Macino G. (1992) Quelling: transient inactivation of gene expression in Neurospora crassa by transformation with homologous sequences. Mol. Microbiol. 6, 3343-3453.
52. Santel A. Aleku M. Keil O. et al. (2006a) A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther., E-pub ahead of print 20 April 2006, doi 10.1038/sj.gt.3302777.
53. Santel A., Aleku M., Keil O. et al. (2006b) RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther., E-pub ahead of print 20 April 2006. doi: 10.1038/sj.gt.3302778.
54. Scholz. J. and Woolf C. J. (2002) Can we conquer pain? Nat. Neurosci. 5, 1062-1067.
55. Seibler J., Kuter-Luks B., Kern H., Streu S., Plum L., Mauer J., Kuhn R., Bruning J. C. and Schwenk F. (2005) Single copy shRNA configuration for ubiquitous gene knockdown in mice. Nucleic Acids Res. 33, e67.
56. Shi Y. (2002) Mammalian RNAi for the masses. Trends Genet. 19, 9-12.
57. Sledz C. A., Holko M., de Veer M. J., Silverman R. H. and Williams B. R. (2003) Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5, 834-839.
58. Song E., Zhu P., Lee S. K. et al. (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709-717.
59. Soutchek J., Akinc A., Bramlage B. et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178.
60. Stark G. R., Kerr I. M., Williams B. R., Silverman R. H. and Schreiber R. D. (1998) How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264.
61. Stone L. S. and Vulchanova L. (2003) The pain of antisense: in vivo application of antisense oligonucleotides for functional genomics in pain and analgesia. Advanced Drug Dev. Rev. 55, 1081-1112.
62. Tan P.-H., Yang L.-C., Shih H.-C., Lan K.-C. and Cheng J.-T. (2005) Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther. 12, 59-66.
63. Thakker D. R., Natt F., Hüsken D., Maier R., Müller M., van der Putten H., Hoyer D. and Cryan J. F. (2004) Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc. Natl Acad. Sci. USA 101, 17 270-17 275.
64. Tominaga M. and Tominaga T. (2005) Structure and function of TRPV1. Pflugers Arch. 451, 143-150.
65. Trülzsch B. and Wood M. (2004) Applications of nucleic acid technology in the CNS. J. Neurochem. 88, 257-265.
66. van de Wetering M., Oving I., Muncan V. et al. (2003) Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Report 6, 609-615.
67. Xia H., Mao Q., Eliason S. L. et al. (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10, 816-820.
68. Xia H., Mao Q., Paulson H. L. and Davidson B. L. (2002) siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. 20, 1006-1010.
69. Zamore P. D., Tuschl T., Sharp P. A. and Bartel D. P. (2000) RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21-23 nucleotide intervals. Cell 101, 25-33.
70. Zhang Y. F., Boado R. J. and Pardridge W. M. (2003b) In vivo knock-down of gene expression in brain cancer with intravenous RNAi in adult rats. J. Gene Med. 5, 1039-1045.
71. Zhang Y. F., Boado R. J. and Pardridge W. M. (2003c) Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm. Res. 20, 1779-1785.
72. Zhang X., Huang J. and McNaughton P. A. (2005) NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J. 24, 4211-4223.
73. Zhang W. B., Zhang Z., Ni Y. X., Wu Y. L. and Pei G. (2003a) A novel function of Goalpha: mediation of extracellular signal-regulated kinase activation by opioid receptors in neural cells. J. Neurochem. 86, 1213-1222.
74. Zimmermann T. S., Lee A. C. H., Akinc A. et al. (2006) RNAi-mediated gene silencing in non-human primates. Nature 441, 111-114.